NCT05292443: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer |
|
|
| Withdrawn | N/A | 300 | RoW | Observation | Geneplus-Beijing Co. Ltd., Eastern Hepatobiliary Surgery Hospital | Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma | 03/23 | 03/23 | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
